乌诺前列酮
|
|
|
- CAS号:
- 120373-36-6
- 英文名:
- UNOPROSTONE
- 英文别名:
- UNOPROSTONE;Unii-6X4F561V3w;Unoprostone [inn];Emorfazone Impurity 6;Alprostadil Impurity 20;13,14-DIHYDRO-15-KETO-20-ETHYL PROSTAGLANDIN F2ALPHA;9ALPHA, 11ALPHA-DIHYDROXY-15-OXO-20A,20B-DIHOMOPROST-5-EN-1-OIC ACID;(E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoic acid;5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, (5Z)-
- 中文名:
- 乌诺前列酮
- 中文别名:
- 乌诺前列酮 1KG;化合物 T13955
- CBNumber:
- CB7220472
- 分子式:
- C22H38O5
- 分子量:
- 382.53
- MOL File:
- 120373-36-6.mol
|
|
|
乌诺前列酮化学性质
-
沸点:
-
562.9±40.0 °C(Predicted)
-
|
-
密度:
-
1.069±0.06 g/cm3(Predicted)
-
|
-
储存条件:
-
Store at -20°C
-
|
-
溶解度:
-
DMF: 25 mg/ml; DMSO: 17 mg/ml; Ethanol: 12 mg/ml; PBS (7.2): 90 μg/ml
-
|
-
酸度系数(pKa):
-
4.76±0.10(Predicted)
-
|
乌诺前列酮性质、用途与生产工艺
Unoprostone 是一种前列腺素 F2α 类似物 (PGAs)，可通过激活 BK 通道来减少氧化应激和光诱导的视网膜细胞死亡以及吞噬功能障碍。Unoprostone 可以降低眼内压，局部用于青光眼或高眼压症。
Pretreatment with Unoprostone (0.01, 0.1, 1 μM; 1 h before H
2
O
2
treatment) protects against H
2
O
2
-induced cell death in a concentration-dependent manner and the effect is significant at 0.1 μM and 1 μM concentrations.
Pretreatment with Unoprostone at concentrations of 0.1 to 3 μM protects against light-induced cell death in a concentration-dependent manner; the effect is significant at the 1 and 3 μM concentrations. Unoprostone reduces the morphological change, and it significantly inhibits the low mitochondrial membrane potential and cell death induced by light irradiation.
Unoprostone has prostaglandin F
2α
receptors (FP) binding affinity with a K
i
of 3.86 μM.
Cell Viability Assay
|
Cell Line:
|
H
2
O
2
-induced photoreceptor cell
|
|
Concentration:
|
0.01, 0.1, 1 μM
|
|
Incubation Time:
|
1 hour before H
2
O
2
treatment
|
|
Result:
|
Protected against H
2
O
2
-induced cell death in a concentration-dependent manner.
|
Unoprostone (0.06%, 0.12%; topical instillation; 3 µl) reduces mouse intraocular pressure (IOP) in a dose-dependent manner.
|
Animal Model:
|
Male mice (6 weeks old)
|
|
Dosage:
|
0.06%, 0.12%
|
|
Administration:
|
Topical instillation; 3 µl
|
|
Result:
|
Reduced mouse IOP in a dose-dependent manner.
|
乌诺前列酮
上下游产品信息
上游原料
下游产品
乌诺前列酮
生产厂家
全球有 42家供应商
乌诺前列酮国内生产厂家
120373-36-6, 乌诺前列酮 相关搜索:
- 药靶配体
- 化合物 T13955
- 乌诺前列酮 1KG
- 120373-36-6
- Emorfazone Impurity 6
- Alprostadil Impurity 20
- 5-Heptenoic acid, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-, (5Z)-
- (E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoic acid
- 13,14-DIHYDRO-15-KETO-20-ETHYL PROSTAGLANDIN F2ALPHA
- Unoprostone [inn]
- Unii-6X4F561V3w
- 9ALPHA, 11ALPHA-DIHYDROXY-15-OXO-20A,20B-DIHOMOPROST-5-EN-1-OIC ACID
- UNOPROSTONE